AR029766A1 - QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION - Google Patents
QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR029766A1 AR029766A1 ARP000104887A ARP000104887A AR029766A1 AR 029766 A1 AR029766 A1 AR 029766A1 AR P000104887 A ARP000104887 A AR P000104887A AR P000104887 A ARP000104887 A AR P000104887A AR 029766 A1 AR029766 A1 AR 029766A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- inhibitor compound
- quinase
- pharmaceutical composition
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
Un compuesto inhibidor de quinasa de Formula 1, las mezclas racémicas diastereoméricas, isomeros opticos, sales farmacéuticamente aceptables, prodrogas o metabolitos biologicamente activos del mismo, los que se seleccionan del grupo compuesto por formulas 1 a 117 en donde R1, R2 y R3 son como se describen en la memoria. Uso de un compuesto de Formula 1 o una sal farmacéuticamente aceptable, prodroga o metabolitos biologicamente activos del mismo, para preparar una composicion de utilidad para inhibir una o más actividades de proteína quinasa en un paciente.A kinase inhibitor compound of Formula 1, the diastereomeric racemic mixtures, optical isomers, pharmaceutically acceptable salts, prodrugs or biologically active metabolites thereof, which are selected from the group consisting of formulas 1 to 117 wherein R1, R2 and R3 are as They are described in memory. Use of a compound of Formula 1 or a pharmaceutically acceptable salt, prodrug or biologically active metabolites thereof, to prepare a useful composition for inhibiting one or more protein kinase activities in a patient.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15461899P | 1999-09-17 | 1999-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029766A1 true AR029766A1 (en) | 2003-07-16 |
Family
ID=22552056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104887A AR029766A1 (en) | 1999-09-17 | 2000-09-18 | QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP1268481B1 (en) |
JP (1) | JP2003509427A (en) |
KR (1) | KR20020063854A (en) |
CN (1) | CN1390220A (en) |
AR (1) | AR029766A1 (en) |
AT (1) | ATE380814T1 (en) |
AU (1) | AU7491400A (en) |
BG (1) | BG106585A (en) |
BR (1) | BR0014075A (en) |
CA (1) | CA2385769A1 (en) |
CY (1) | CY1107886T1 (en) |
CZ (1) | CZ2002934A3 (en) |
DE (1) | DE60037455T2 (en) |
DK (1) | DK1268481T3 (en) |
ES (1) | ES2299434T3 (en) |
HK (1) | HK1053831A1 (en) |
HU (1) | HUP0303363A2 (en) |
IL (1) | IL148719A0 (en) |
MX (1) | MXPA02002938A (en) |
NO (1) | NO20021329L (en) |
NZ (1) | NZ517759A (en) |
PL (1) | PL354241A1 (en) |
PT (1) | PT1268481E (en) |
SK (1) | SK3792002A3 (en) |
TR (1) | TR200201506T2 (en) |
WO (1) | WO2001019828A2 (en) |
ZA (1) | ZA200202122B (en) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
ES2372028T3 (en) | 2000-10-23 | 2012-01-13 | Glaxosmithkline Llc | NEW COMPOSITE OF 8H-PIRIDO [2,3-D] PIRIMIDIN-7-ONA, REPLACED FOR THE TREATMENT OF DISEASES MEDIATED BY THE CSBP / P38 QUINASA. |
AU2002333524A1 (en) | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
MXPA04007961A (en) * | 2002-02-22 | 2004-11-26 | Teijin Ltd | Pyrrolopyrimidine derivative. |
US7560552B2 (en) | 2002-03-21 | 2009-07-14 | Abbott Laboratories | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
RU2004133811A (en) | 2002-04-19 | 2005-04-20 | Смитклайн Бичам Корпорейшн (US) | NEW COMPOUNDS |
AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
JP2006528685A (en) * | 2003-05-06 | 2006-12-21 | スミスクライン ビーチャム コーポレーション | New compounds |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
CN1860118A (en) * | 2003-07-29 | 2006-11-08 | Irm责任有限公司 | Compounds and compositions as protein kinase inhibitors |
EP1699800B1 (en) * | 2003-12-23 | 2010-02-10 | Novartis AG | Bicyclic heterocyclic p-38 kinase inhibitors |
TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
JP2007538068A (en) * | 2004-05-19 | 2007-12-27 | アストラゼネカ アクチボラグ | Novel fused heterocycles and their use |
FR2871158A1 (en) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
MX2007005120A (en) | 2004-10-29 | 2007-07-16 | Abbott Lab | Novel kinase inhibitors. |
DE102004061288A1 (en) | 2004-12-14 | 2006-06-29 | Schering Ag | New 3-amino-pyrazolo(3,4b)pyridine derivatives are protein tyrosine kinases inhibitors useful e.g. for treating hyperproliferation of body cells, neurodegenerative disease, blood vessel disease and angiogenic disease |
PE20061119A1 (en) | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PYRAZOLO PYRIDINES SUBSTITUTED AS INHIBITORS OF FAK, KDR AND Tie KINASES |
US7842809B2 (en) | 2005-01-24 | 2010-11-30 | Bayer Schering Pharma Ag | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same |
EP1683796A1 (en) * | 2005-01-24 | 2006-07-26 | Schering Aktiengesellschaft | Pyrazolopyridines, their preparation and their medical use |
US20100047338A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
PE20100741A1 (en) | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38 |
MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
JP2008535822A (en) | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | New compounds |
JP2008537937A (en) | 2005-03-25 | 2008-10-02 | グラクソ グループ リミテッド | Process for producing pyrido [2,3-d] pyrimidin-7-one and 3,4-dihydropyrimido [4,5-d] pyrimidin-2 (1H) -one derivatives |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US7795248B2 (en) | 2005-05-18 | 2010-09-14 | Abbott Laboratories, Inc. | Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors |
FR2889526B1 (en) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
DE102005042742A1 (en) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals |
TW200800983A (en) * | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
JP2009507924A (en) * | 2005-09-14 | 2009-02-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 5-oxo-5,8-dihydro-pyrido-pyrimidines as c-fms kinase inhibitors |
AU2006316605B2 (en) | 2005-11-17 | 2012-04-26 | Osi Pharmaceuticals, Inc. | Fused bicyclic mTOR inhibitors |
WO2007064931A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
PE20070855A1 (en) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS |
EP1981890A2 (en) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
DE602007008837D1 (en) * | 2006-02-14 | 2010-10-14 | Vertex Pharma | AS PROTEIN KINASE INHIBITORS USEFUL DYHYDRODIAZEPINE |
US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US20100234351A1 (en) * | 2006-02-23 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Fused nitrogen-comprising heterocyclic compound |
TW200815437A (en) * | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
WO2008022060A2 (en) * | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008043019A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
WO2008113711A1 (en) | 2007-03-22 | 2008-09-25 | F. Hoffmann-La Roche Ag | Substituted pyrimidodiazepines useful as plk1 inhibitors |
CA2686485A1 (en) | 2007-05-23 | 2008-11-27 | Pharmacopeia, Llc | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
DE102007024470A1 (en) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | New sulfoximine-substituted quinoline and/or quinazoline derivatives are erythropoietin-producing hepatoma amplified sequence-receptor kinase inhibitors useful to prepare medicaments to e.g. treat endometriosis and stenosis |
US20110201818A1 (en) | 2007-09-25 | 2011-08-18 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
EP2072502A1 (en) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors |
CN101239978A (en) * | 2008-03-05 | 2008-08-13 | 南方医科大学 | Imidazopyridines compounds |
AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
JP2011527667A (en) | 2008-06-18 | 2011-11-04 | 武田薬品工業株式会社 | Halo-substituted pyrimidodiazepine |
CA2743592A1 (en) | 2008-12-05 | 2010-06-10 | Abbott Laboratories | Thienopyridine kinase inhibitors with improved cyp safety profile |
CA2761389A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
NZ599356A (en) | 2009-09-25 | 2013-08-30 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
KR20120096474A (en) | 2009-09-25 | 2012-08-30 | 버텍스 파마슈티칼스 인코포레이티드 | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
CN102918042B (en) * | 2010-02-08 | 2016-03-09 | 默沙东有限责任公司 | 8-methyl isophthalic acid-phenyl imidazole [1,5-a] pyrazine compound |
NZ603643A (en) * | 2010-05-31 | 2014-07-25 | Ono Pharmaceutical Co | Purinone derivative |
AU2015202128B2 (en) * | 2010-05-31 | 2015-05-28 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
DK3689878T3 (en) | 2011-07-19 | 2021-11-08 | Merck Sharp & Dohme | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US8436179B2 (en) | 2011-07-20 | 2013-05-07 | Abbvie Inc. | Kinase inhibitor with improved solubility profile |
RU2750538C2 (en) | 2011-11-29 | 2021-06-29 | Оно Фармасьютикал Ко., Лтд. | Purinone derivative hydrochloride |
UY34484A (en) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES |
WO2013087647A1 (en) | 2011-12-15 | 2013-06-20 | Bayer Intellectual Property Gmbh | Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer |
US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
CA2865021C (en) | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
BR112014029718A2 (en) | 2012-05-31 | 2017-06-27 | Pharmascience Inc | protein kinase inhibitors |
CA2782774A1 (en) | 2012-07-06 | 2014-01-06 | Pharmascience Inc. | Protein kinase inhibitors |
CN103655566B (en) * | 2012-09-10 | 2016-12-21 | 杨子娇 | Compound purposes in the medicine of preparation preventing and treating glaucoma |
CN105796569A (en) * | 2012-09-10 | 2016-07-27 | 杨子娇 | Application of compound to preparation of drug for preventing and treating glaucoma |
WO2014114185A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP4066841A1 (en) | 2013-03-14 | 2022-10-05 | University of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
US9637487B2 (en) * | 2013-07-02 | 2017-05-02 | Pharmacyclics Llc | Purinone compounds as kinase inhibitors |
AU2014306698A1 (en) | 2013-08-12 | 2016-01-28 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
CA2833867A1 (en) | 2013-11-21 | 2015-05-21 | Pharmascience Inc. | Protein kinase inhibitors |
WO2015083008A1 (en) | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
US9834554B2 (en) | 2013-12-20 | 2017-12-05 | Merck Sharp & Dohme Corp. | BTK inhibitors |
EP3082809B1 (en) | 2013-12-20 | 2021-01-20 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US10428331B2 (en) | 2014-01-16 | 2019-10-01 | Musc Foundation For Research Development | Targeted nanocarriers for the administration of immunosuppressive agents |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
WO2015146159A1 (en) | 2014-03-25 | 2015-10-01 | Ono Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma |
WO2015181633A2 (en) | 2014-04-11 | 2015-12-03 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
TW201613644A (en) | 2014-06-17 | 2016-04-16 | Acerta Pharma Bv | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor |
PL3179991T3 (en) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
ES2955554T3 (en) | 2015-04-09 | 2023-12-04 | Ono Pharmaceutical Co | Process to produce a purinone derivative |
PT3954690T (en) | 2015-07-02 | 2023-06-06 | Acerta Pharma Bv | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
CN105130932B (en) * | 2015-07-14 | 2017-06-16 | 中国科学院微生物研究所 | Compound and its purposes in the medicine for preparing PTP1B inhibitor and treatment and/or prevention type II diabetes |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
KR20230111268A (en) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Pyrrolotriazine compounds as tam inhibitors |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
BR112019004586A2 (en) | 2016-09-09 | 2019-06-11 | Incyte Corp | pyrazolopyridine derivatives as hpk1 modulators and their uses for cancer treatment |
TW201811799A (en) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | Pyrazolopyrimidine compounds and uses thereof |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
MD3687996T2 (en) | 2017-09-27 | 2022-04-30 | Incyte Corp | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
SG11202007917VA (en) | 2018-02-20 | 2020-09-29 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
AR117600A1 (en) | 2018-06-29 | 2021-08-18 | Incyte Corp | FORMULATIONS OF AN AXL / MER INHIBITOR |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (en) | 2018-09-25 | 2022-05-11 | Incyte Corp | PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS |
EP4010338A1 (en) | 2019-08-06 | 2022-06-15 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU748884B2 (en) * | 1997-03-19 | 2002-06-13 | Abbott Gmbh & Co. Kg | Pyrrolo(2,3d)pyrimidines and their use as tyrosine kinase inhibitors |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
-
2000
- 2000-09-15 PL PL00354241A patent/PL354241A1/en not_active Application Discontinuation
- 2000-09-15 IL IL14871900A patent/IL148719A0/en unknown
- 2000-09-15 NZ NZ517759A patent/NZ517759A/en unknown
- 2000-09-15 CZ CZ2002934A patent/CZ2002934A3/en unknown
- 2000-09-15 SK SK379-2002A patent/SK3792002A3/en unknown
- 2000-09-15 JP JP2001523405A patent/JP2003509427A/en not_active Withdrawn
- 2000-09-15 BR BR0014075-9A patent/BR0014075A/en not_active IP Right Cessation
- 2000-09-15 AU AU74914/00A patent/AU7491400A/en not_active Abandoned
- 2000-09-15 DE DE60037455T patent/DE60037455T2/en not_active Expired - Lifetime
- 2000-09-15 HU HU0303363A patent/HUP0303363A2/en unknown
- 2000-09-15 EP EP00963510A patent/EP1268481B1/en not_active Expired - Lifetime
- 2000-09-15 WO PCT/US2000/025357 patent/WO2001019828A2/en active IP Right Grant
- 2000-09-15 CN CN00815776A patent/CN1390220A/en active Pending
- 2000-09-15 AT AT00963510T patent/ATE380814T1/en active
- 2000-09-15 KR KR1020027003507A patent/KR20020063854A/en not_active Application Discontinuation
- 2000-09-15 DK DK00963510T patent/DK1268481T3/en active
- 2000-09-15 MX MXPA02002938A patent/MXPA02002938A/en unknown
- 2000-09-15 CA CA002385769A patent/CA2385769A1/en not_active Abandoned
- 2000-09-15 PT PT00963510T patent/PT1268481E/en unknown
- 2000-09-15 ES ES00963510T patent/ES2299434T3/en not_active Expired - Lifetime
- 2000-09-15 TR TR2002/01506T patent/TR200201506T2/en unknown
- 2000-09-18 AR ARP000104887A patent/AR029766A1/en unknown
-
2002
- 2002-03-14 ZA ZA200202122A patent/ZA200202122B/en unknown
- 2002-03-18 NO NO20021329A patent/NO20021329L/en not_active Application Discontinuation
- 2002-04-05 BG BG106585A patent/BG106585A/en unknown
-
2003
- 2003-06-19 HK HK03104425.4A patent/HK1053831A1/en unknown
-
2008
- 2008-02-14 CY CY20081100173T patent/CY1107886T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ATE380814T1 (en) | 2007-12-15 |
IL148719A0 (en) | 2002-09-12 |
DK1268481T3 (en) | 2008-05-05 |
CN1390220A (en) | 2003-01-08 |
PL354241A1 (en) | 2003-12-29 |
HUP0303363A2 (en) | 2004-07-28 |
NZ517759A (en) | 2004-04-30 |
WO2001019828A3 (en) | 2001-10-04 |
DE60037455T2 (en) | 2008-11-27 |
SK3792002A3 (en) | 2003-09-11 |
ES2299434T3 (en) | 2008-06-01 |
EP1268481B1 (en) | 2007-12-12 |
CA2385769A1 (en) | 2001-03-22 |
JP2003509427A (en) | 2003-03-11 |
NO20021329D0 (en) | 2002-03-18 |
HK1053831A1 (en) | 2003-11-07 |
BG106585A (en) | 2003-03-31 |
CY1107886T1 (en) | 2013-06-19 |
EP1268481A2 (en) | 2003-01-02 |
CZ2002934A3 (en) | 2002-07-17 |
AU7491400A (en) | 2001-04-17 |
MXPA02002938A (en) | 2004-12-06 |
KR20020063854A (en) | 2002-08-05 |
TR200201506T2 (en) | 2002-10-21 |
NO20021329L (en) | 2002-05-21 |
WO2001019828A2 (en) | 2001-03-22 |
PT1268481E (en) | 2008-03-19 |
DE60037455D1 (en) | 2008-01-24 |
BR0014075A (en) | 2002-07-16 |
ZA200202122B (en) | 2003-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029766A1 (en) | QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION | |
CO5580767A2 (en) | INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE | |
CO5271715A1 (en) | 7-AZA-INDOLIN-2-WAVES SUBSTITUTED IN 4 AND ITS USE AS PROTEIUNA QUINASA INHIBITORS | |
DK1263730T3 (en) | Amine derivatives for the treatment of apoptosis | |
CO4810375A1 (en) | DERIVATIVES OF 9-AMINO-3-KETO Erythromycin | |
ECSP045483A (en) | DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR USE | |
AR032136A1 (en) | USEFUL ESPIROHETEROCICLIC COMPOUNDS AS REVERSIBLE CISTEINE-PROTEASES INHIBITORS | |
AR029634A1 (en) | USEFUL HETEROCICLIC DERIVATIVE COMPOUNDS AS ANTI-TARGET AGENTS, PHARMACEUTICAL COMPOSITION AND PROCESSING PROCEDURE | |
UY27226A1 (en) | PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS | |
UY27222A1 (en) | PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS | |
AR008164A1 (en) | CETOLIDES 6-0-SUBSTITUTES THAT HAVE ANTIBACTERIAL ACTIVITY, PROCEDURES FOR THEIR PREPARATION, USE OF THE SAME IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS | |
CR6643A (en) | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | |
PA8591701A1 (en) | PIRROLOPIRIMIDINE DERIVATIVES | |
AR030933A1 (en) | TRIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR008377A1 (en) | A COMPOUND DERIVED FROM 3-AROYLBENCIL-PIRIDAZINONE, A PARTICULAR PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES CONTAINING SUCH A COMPOUND | |
ECSP045004A (en) | INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF DEPENDING ANDROGEN DISEASES | |
TR200201505T2 (en) | Pirazolopyrimidines as therapeutic agents | |
ECSP066383A (en) | DERIVATIVES OF 5-PHENYL-4-METHYL-TIAZOL-2-IL-AMINA AS INHIBITORS OF KINASA ENZYMES PHOSFATIDILINOSITOL 3 (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE RESPIRATORY ROUTES | |
UY27350A1 (en) | AZAINDOLS | |
UY26968A1 (en) | THERAPEUTIC AGENTS | |
UY28671A1 (en) | PIRIDO (2.3-D) PIRIMIDINA-2,4-DIAMINAS AS PDE 2 INHIBITORS | |
PA8495101A1 (en) | DERIVATIVES OF 13-METHYLERITROMYCIN | |
NO20025641D0 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
NO20025640D0 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
UY27803A1 (en) | DERIVATIVES OF BENZOXAZINE AND USES OF THE SAME. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |